reason
wide
variat
sever
coronaviru
diseas
across
affect
countri
world
known
two
recent
studi
suggest
link
bcg
vaccin
polici
morbid
mortal
due
present
studi
compar
impact
term
case
fatal
rate
cfr
countri
high
diseas
burden
bcg
revaccin
polici
presum
revaccin
practic
would
provid
ad
protect
popul
sever
found
signific
differ
cfr
two
group
countri
data
support
view
univers
bcg
vaccin
protect
effect
cours
probabl
prevent
progress
sever
diseas
death
clinic
trial
bcg
vaccin
urgent
need
establish
benefici
role
suggest
epidemiolog
data
especi
countri
without
univers
bcg
vaccin
polici
ongo
pandem
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
pose
grave
threat
global
public
health
one
million
confirm
case
global
death
toll
alarmingli
cross
april
climat
fear
social
disrupt
institut
breakdown
scientif
uncertainti
devast
caus
pandem
probabl
parallel
spanish
flu
pandem
still
consid
devast
human
histori
affect
estim
one
third
world
popul
time
die
world
govern
work
tandem
health
organis
make
possibl
effort
establish
countermeasur
reduc
devast
effect
world
top
healthcar
system
appear
shaken
pandem
forc
medic
fratern
realis
someth
basic
life
alway
doctor
hand
feel
doctor
never
pandem
sinc
definit
treatment
effect
vaccin
diseas
control
scientif
commun
make
frenet
effort
find
measur
cure
least
reduc
morbid
due
larg
number
therapeut
measur
lowdos
methylprednisolon
chloroquin
phosphat
hydroxychloroquin
ribavirin
angiotensin
receptor
blocker
antiag
drug
azithromycin
quercetin
rapamycin
doxycyclin
suppressor
proteas
inhibitor
lopinavirritonavir
acetazolamid
nifedipin
phosphodiesteras
inhibitor
convalesc
plasma
transfus
tocilizumab
tradit
chines
medicin
statin
zinc
supplement
therapeut
neutral
monoclon
antibodi
either
tri
suggest
patient
short
span
month
desper
hope
effect
treatment
patient
commensur
unpreced
time
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
augment
observ
two
publish
studi
hypothes
countri
adopt
bcg
revaccin
polici
past
might
advantag
revaccin
practic
would
sustain
protect
offer
bcg
vaccin
specif
compar
case
fatal
rate
cfr
countri
high
burden
countri
follow
bcg
revaccin
polici
past
accord
bcg
atla
publish
countri
adopt
bcg
revaccin
polici
past
exclud
analysi
due
either
nonavail
inform
nonspecif
age
second
bcg
dose
data
popul
taken
world
popul
clock
inform
number
case
death
retriev
situat
report
day
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
observ
mark
differ
mean
cfr
two
group
countri
versu
p
valu
tabl
data
support
observ
previou
two
studi
miller
adequ
exclud
conclus
drawn
studi
univers
bcg
vaccin
polici
correl
reduc
mortal
rate
due
thu
appear
trustworthi
anoth
conclus
countri
establish
univers
bcg
polici
earlier
reduc
mortal
rate
also
reassur
especi
low
middl
incom
economi
studi
hegarti
pk
et
al
also
arriv
similar
conclus
countri
nation
program
univers
bcg
vaccin
appear
lower
incid
death
rate
studi
recommend
test
hypothesi
bcg
vaccin
probabl
offer
protect
random
control
trial
determin
fast
bcg
induc
protect
immun
respons
develop
protect
offer
bcg
vaccin
attribut
nonspecif
effect
nse
rang
nse
includ
reduct
incid
respiratori
tract
infect
children
antivir
effect
reduc
viremia
experiment
anim
sever
virus
respiratori
syncyti
viru
yellow
fever
herp
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
simplex
viru
human
papilloma
viru
favour
vitro
vivo
effect
inde
observ
variou
studi
base
hypothesi
bcg
vaccin
may
induc
partial
protect
suscept
andor
sever
infect
even
epidem
countri
like
australia
netherland
practic
routin
bcg
vaccin
realli
quick
launch
phase
clinic
trial
limit
studi
calcul
cfr
divid
number
known
death
number
confirm
case
may
repres
true
cfr
ongo
epidem
chose
calcul
numer
denomin
rapidli
chang
use
meant
comparison
project
mortal
due
also
wish
caution
oversimplif
interpret
bcg
vaccin
link
deriv
epidemiolog
data
need
confirm
well
design
clinic
trial
furthermor
cfr
depend
multipl
factor
particular
abil
nation
govern
healthcar
system
respond
epidem
gain
foothold
low
resourc
countri
cfr
may
chang
significantli
current
conclus
may
becom
invalid
sever
low
resourc
countri
india
practic
univers
bcg
vaccin
polici
establish
sinc
midtwentieth
centuri
unlik
develop
countri
tuberculosi
rate
popul
declin
significantli
prompt
polici
maker
adopt
target
bcg
vaccin
approach
high
risk
popul
univers
vaccin
strategi
continu
sever
hightbburden
countri
observ
two
recent
epidemiolog
studi
alongwith
data
offer
hope
reduc
impact
countri
practic
univers
bcg
vaccin
polici
similar
recent
publish
experi
children
instil
optim
amongst
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
